Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 330
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483080/330-10-50-2

Name:	us-gaap_InventoryWriteDown
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Inventory, net - Additional Information (Detail) - Cara Therapeutics, Inc. - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Dec. 17, 2024
Inventory [Line Items]
Inventory write-down	$ 0	$ 0	$ 2,963
Vifor Fresenius Medical Care Renal Pharma Ltd agreement
Inventory [Line Items]
Asset Purchase Agreement				$ 900